| Synergistic effects of sorafenib and celecoxib inhibit growth and VEGF expression in Hec-1A endometrial cancer cell line. |
|
Jeong Sig Kim, Bo Ra Park, Gye Hyun Nam, Dong Han Bae |
1Department of Obstetrics and Gynecology, Soonchunhyang Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea. jskim@schmc.ac.kr
2Department of Obstetrics and Gynecology, Soonchunhyang Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea.
3Department of Obstetrics and Gynecology, Soonchunhyang Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Korea. |
|
|
| Abstract |
OBJECTIVE
The aim of this study was to investigate whether combination of sorafenib and celecoxib exhibited an anti-tumor efficacy or altered expression of vascular endothelial growth factor (VEGF) in Hec-1A endometrial cancer cell line. METHODS: To determine whether sorafenib or celecoxib-induced growth inhibition was determined by the (3-[4,5-dimethylthiazol-2-yl]-5-[3-carboxymethoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazolium, inner salt) assay. Expression of VEGF and p53 were evaluated using the reverse transcription polymerase chain reaction. RESULTS: Combination of sorafenib 10 ng/mL and celecoxib 50 micromol/L exhibited synergistic inhibitory effects compared to treatment with each agent alone (P<0.0001). VEGF expression was also down regulated after 24 hours or 72 hours of treatment with sorafenib alone or in combination with sorafenib and celecoxib in Hec-1A cells. However, there was no alteration of p53 expression in Hec-1A cells after 24 hours or 72 hours of treatment with sorafenib alone or in combination with sorafenib and celecoxib. CONCLUSION: Combination treatment of sorafenib and celecoxib to Hec-1A endometrial cancer cell line revealed the ability to inhibit growth and expression of VEGF. |
| Key Words:
Endometrial cancer, Sorafenib, Celecoxib, Vascular endothelial growth factor |
|
PDF Links
Full text via DOI
Download Citation
